Welcome to our dedicated page for Sophia Genetics Sa SEC filings (Ticker: SOPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SOPHiA GENETICS SA (Nasdaq: SOPH) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. SOPHiA GENETICS files reports such as Form 20-F and Form 6-K with the U.S. Securities and Exchange Commission, offering detailed information on its financial condition, operations, and material announcements related to its AI-powered healthcare technology business.
Recent Form 6-K filings have included unaudited interim condensed consolidated financial statements, management’s discussion and analysis of financial condition and results of operations, and press releases covering quarterly results and business updates. These documents give investors insight into revenue trends, non-IFRS measures such as adjusted gross profit and adjusted EBITDA, geographic revenue breakdowns, and segment information that includes the SOPHiA DDM™ Platform and workflow equipment and services.
Through this page, users can review how SOPHiA GENETICS reports on topics such as platform usage, analysis volumes, regional performance, and capital structure. Filings may also reference warrant liabilities, credit agreements, and other financial instruments, along with discussions of constant currency revenue and other metrics used by management to evaluate performance.
Stock Titan enhances these filings with AI-powered summaries that explain key points in accessible language, helping readers understand complex sections of financial statements and management commentary. Users can quickly identify important themes in SOPHiA GENETICS’ 20-F annual reports, 6-K current reports, and other submissions, and then drill into the original documents for more detail.
In addition, this page offers convenient access to information relevant to governance and capital markets activity, such as exhibits attached to 6-Ks and references to registration statements. While SOPHiA GENETICS is not a U.S. domestic issuer and does not file Forms 10-K or 10-Q, its 20-F and 6-K filings serve a similar role for investors analyzing SOPH stock and the company’s AI-driven precision medicine platform.
SOPHiA GENETICS SA Chief Technology Officer Abhimanyu Verma received new equity awards as part of his compensation. He was granted options to buy 119,760 ordinary shares at an exercise price of $5.04 per share, vesting 25% on April 2, 2027 and monthly through April 2, 2030. He also received 82,136 restricted stock units, with 25% vesting on April 2, 2027 and the remaining 75% in equal quarterly installments through April 2, 2030. These are awards from the company, not open-market purchases or sales.
SOPHiA GENETICS SA granted President Ross Muken equity-based compensation on April 2, 2026. He received options to buy 628,743 ordinary shares at $5.04 per share, exercisable until April 2, 2036, and 431,211 restricted stock units that convert into ordinary shares as they vest.
According to the vesting terms, 25% of the RSUs vest on April 2, 2027, with the remaining 75% vesting in equal quarterly installments through April 2, 2030. The share options vest 25% on April 2, 2027, then in equal monthly installments through April 2, 2030, contingent on continued service.
SOPHiA GENETICS SA Chief Medical Officer Philippe Menu reported new equity awards. He received a grant of 164,671 share options with an exercise price of $5.04 per share, and a separate grant of 112,936 ordinary shares in the form of restricted stock units.
The RSUs were granted under the company’s 2021 Equity Incentive Plan and vest over time, with 25% vesting on April 2, 2027 and the remaining 75% in equal quarterly installments through April 2, 2030, subject to continued service. The options vest as to 25% of the underlying ordinary shares on April 2, 2027, then in equal monthly installments through April 2, 2030, and expire on April 2, 2036. After these awards, Menu directly holds 112,936 ordinary shares and 164,671 share options from this filing.
Chief Scientific Officer Zhenyu Xu received new equity awards from SOPHiA GENETICS SA. On April 2, 2026, he was granted 112,936 ordinary shares as restricted stock units and a share option for 164,671 ordinary shares with a $5.04 exercise price.
The RSUs vest 25% on April 2, 2027, with the remaining 75% vesting in equal quarterly installments through April 2, 2030, subject to continued service. The option vests 25% on April 2, 2027, then in equal monthly installments through April 2, 2030, and expires on April 2, 2036. These are compensation-related grants rather than open-market purchases.
SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong reported equity compensation grants on April 2, 2026. He received 628,743 share options with an exercise price of $5.040 per ordinary share, expiring on April 2, 2036. He also received 431,211 restricted stock units (RSUs), each representing one ordinary share.
The RSUs vest with 25% on April 2, 2027, and the remaining 75% in equal quarterly installments through April 2, 2030, contingent on continued service. The options vest as to 25% on April 2, 2027, with the balance vesting in equal monthly installments through April 2, 2030. These are compensation-related awards, not open-market trades.
SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert reported equity awards consisting of stock options and restricted stock units as part of his compensation. He received options for 82,335 ordinary shares at an exercise price of $5.04 per share, expiring on April 2, 2036. These options vest 25% on April 2, 2027, then in equal monthly installments through April 2, 2030. He also received 56,468 restricted stock units, each representing one ordinary share, with 25% vesting on April 2, 2027 and the remaining 75% vesting in equal quarterly installments through April 2, 2030. These are awards, not open-market purchases or sales.
SOPHiA GENETICS SA disclosed that Chief Financial Officer George Cardoza received new equity awards. He was granted 164,671 share options with an exercise price of $5.04 per ordinary share, expiring on April 2, 2036, and 112,936 ordinary shares as restricted stock units (RSUs). These are compensation-related grants, not open-market purchases.
The RSUs vest 25% on April 2, 2027, with the remaining 75% vesting in equal quarterly installments through April 2, 2030. The share options vest 25% on April 2, 2027, then in equal monthly installments through April 2, 2030. After these grants, Cardoza directly holds 112,936 ordinary shares and options for 164,671 shares, aligning his compensation further with long-term company performance.
SOPHiA GENETICS SA Chief People Officer Manuela Valente received new equity awards tied to her role. She was granted share options for 104,790 ordinary shares at an exercise price of $5.04 per share, expiring on April 2, 2036. She also received 71,869 restricted stock units (RSUs), each representing one ordinary share upon vesting.
According to the vesting terms, 25% of the RSUs will vest on April 2, 2027, with the remaining 75% vesting in equal quarterly installments through April 2, 2030, conditioned on continued service. The share options vest as to 25% on April 2, 2027, then in equal monthly installments through April 2, 2030.
Van Well Daan reported acquisition or exercise transactions in this Form 4 filing.
SOPHiA GENETICS SA reported that Chief Legal Officer Daan Van Well received new equity compensation. He was granted options to buy 142,216 ordinary shares at $5.0400 per share, expiring on April 2, 2036. These options vest 25% on April 2, 2027, then in equal monthly installments through April 2, 2030.
He was also granted 97,536 restricted stock units (RSUs), each representing one ordinary share. For these RSUs, 25% vest on April 2, 2027, with the remaining 75% vesting in equal quarterly installments through April 2, 2030. These are compensation-related awards, not open-market share purchases or sales.
SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert had 3 Ordinary Shares sold in the open market at $4.71 per share. According to the disclosure, the sale was a “sell to cover” transaction to satisfy tax obligations from restricted stock units that vested on March 30, 2026, and was not a discretionary trade. Following this small tax-related sale, he holds 92,383 Ordinary Shares directly.